Nationwide Raptiva® Lawsuit

On February 19, 2009, the U.S. Food & Drug Administration (FDA) issued a Public Health Advisory warning of serious, life-threatening side effects associated with the psoriasis drug Raptiva (efalizumab).

Raptiva has been linked to progressive multifocal leukoencephalopathy (PML), a rare brain infection that often leads to death among patients diagnosed.

If you or a loved one have used Raptiva (efalizumab) and developed progressive multifocal leukoencephalopathy (PML), you should contact us immediately. You may be entitled to compensation for your injuries or unfortunate loss and we can help.

What’s the problem?

In October 2008, the FDA added a “black box warning” to Raptiva (efalizumab), which warned psoriasis patients of the risks of life-threatening infections, including progressive multifocal leukoencephalopathy, also known as PML.

Recently, in February 2009 the FDA issued a Public Healh Advisory after receiving three confirmed reports of Raptiva patients developing PML. Unfortunately, all three Raptiva patients that developed PML died.

The FDA strongly recommends that health care professionals carefully monitor patients on Raptiva, as well as those who have discontinued the drug, for any signs or symptoms of neurologic disease, and that they periodically reassess the benefits of continued treatment.

FDA Video: Serious Infections and Neurological Events with Raptiva

In February 2009, the U.S. Food & Drug Administration (FDA) issued the video below warning of the risk of life-threatening infections in patients treated with Raptiva (efalizumab).

Read the Full Transcript: Serious Infections and Neurological Events with Raptiva

FDA Video: Raptiva (for psoriasis) Withdrawn from Market

On April 8, 2009 the U.S. Food & Drug Administration (FDA) in association with Genentech began a phased market withdrawal (Raptiva recall) of the psoriasis drug Raptiva (efalizumab).  Included below is a video issued from the FDA regarding the Raptiva recall.

Read the Full Transcript: Raptiva (for psoriasis) Withdrawn from Market

What is Progressive Multifocal Leukoencephalopathy?

PML is caused by a virus that affects the central nervous system. PML usually occurs in people whose immune systems have been severely weakened. It leads to an irreversible decline in neurologic function and death.

What are the symptoms of Progressive Multifocal Leukoencephalopathy?

The most common symptoms associated with the development of PML may include:

• unusual weakness
• loss of coordination
• changes in vision
• difficulty speaking
• personality change

Do I Have a Raptiva (efalizumab) Lawsuit?

The Defective Drugs & Products Liability Litigation Group at our law firm is an experienced team of trial lawyers that focus exclusively on the representation of plaintiffs in Raptiva lawsuits. We are pursuing individual litigation nationwide and currently accepting new Raptiva induced Progressive Multifocal Leukoencephalopathy, PML and/or brain infection cases in all 50 states.

If you or a loved one have used Raptiva (efalizumab) and developed progressive multifocal leukoencephalopathy (PML), you should contact us immediately. You may be entitled to compensation for your injuries or unfortunate loss and we can help.